Navigation Links
Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
Date:7/21/2008

e inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such expressed or implied forward looking statements could include, among others: our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertaint
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Lorus Therapeutics Receives $600 Thousand From Escrow Account
2. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
3. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
4. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
7. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
8. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
11. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 ... announced that a team from Iowa State University won ... design contest. Using a Convey HC-2ex, the team’s solution ... 14 times faster than the second place finisher. , ... world embarked upon the month long challenge, using a ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech , ... tackling big healthcare problems, announced today the closing ... with participation from Invesco Perpetual, a $120 Billion ... to drive PureTech,s existing pipeline forward and to ... has the scientific creativity to really go for ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th Annual ... take place at the Congress Center Basel, ... now available at http://www.abim.ch . ... from all over the globe will exchange ... products and developments on the world market. ...
(Date:10/19/2014)... 19, 2014 The report "Chocolate, Cocoa ... Trade, Prices, Geography Trend and Forecast (2011 - 2016)," ... and geography and studies the major market drivers, restraints, ... Europe, and Asia. , The global chocolate market is ... billion in 2016 at an estimated CAGR of 2.7% ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... Name is PROLOR Biotech, Inc.- , , -Will Now ... Re-Election of Board of Directors and Other Proposals- , ... Board: MODG) today announced that shareholders approved a proposal to ... Annual Meeting of Shareholders held on May 21, 2009. ...
... June 11 At a meeting of its Board of ... on the Common Stock of the Company. , , A dividend ... Stock was declared payable on September 1, 2009 to stockholders of record ... , Wyeth is one of the world,s largest research-driven pharmaceutical and ...
... 11 Allied Minds has established SoundCure, Inc. to ... in the ear). Allied Minds, a seed investment corporation ... the initial funding and has partnered with the ... LLC to commercialize a novel acoustic therapy for the ...
Cached Biology Technology:Modigene Shareholders Approve Company Name Change and Other Proposals at Annual Meeting 2Allied Minds Establishes New Company to Commercialize Novel UC Irvine Tinnitus Therapy 2
(Date:10/14/2014)... of fish oil supplements, rich in omega-3 fatty acids, do ... in which the heart can beat as fast as 150 ... by the Montreal Heart Institute were published in the ... 7th. , For the trial, 337 patients with atrial fibrillation ... grams of fish oil a day or to placebo for ...
(Date:10/14/2014)... led by the Chinese Academy of Agricultural Sciences in ... a brief genomic history of tomato breeding, based on ... The C.M. Rick Tomato Genetics Resource Center at UC ... providing seed of both cultivated tomato varieties and related ... first tomato genome sequence completed just two years ago, ...
(Date:10/14/2014)... Researchers from Stanford University School of Medicine have discovered ... and the activation of muscle stem cells. Cells use ... during times of nutrient deprivation. The scientists report in ... mechanism is operational it also seems to assist in ... when stem cells emerge from a quiescent state there ...
Breaking Biology News(10 mins):Autophagy helps fast track stem cell activation 2
... Energy Secretary Steven Chu today announced the largest ever ... research projects - using computer simulations to perform virtual ... impractical in the natural world. Utilizing two world-leading supercomputers ... laptops, the research could, for example, help speed the ...
... Although REDD will probably not be officially accepted ... are already under way in the tropical region. ... will combine lower resolution but full area coverage optical ... high resolution satellite data and ground data. The very ...
... epidemic and on the rise in young adults. Using ... Physical Activity and Weight Management Research Center will offer ... study, one of seven clinical trials to be funded ... Lung, and Blood Institute. NIH,s Early Adult Reduction ...
Cached Biology News:Could 135,000 laptops help solve the energy challenge? 2Could 135,000 laptops help solve the energy challenge? 3Could 135,000 laptops help solve the energy challenge? 4Pitt researcher receives NIH funding for technology-enhanced weight-loss program 2Pitt researcher receives NIH funding for technology-enhanced weight-loss program 3
... long and outstanding history in the ... ago we became aware that our ... modified to inject Xenopus oocytes. We ... microdispenser to eliminate any tip movement ...
...
... These primers are designed for sequencing ... the SP6, T7, or T3 RNA polymerase ... They are supplied at a concentration of ... functionally tested in DNA sequencing reactions using ...
... with AutoGen AutoGenesys, BioRobotics BioPick, BioGrid, TAS ... picking systems This CLS number is a ... Cornings product number. If showing no availability ... number (D9314) or contact customer service for ...
Biology Products: